Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 NSCLC 3 Adenocarcinoma of Lung 2 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 Meningeal Carcinomatosis 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Docetaxel 5 Pemetrexed 4 Capecitabine 4 pembrolizumab 3 Oxaliplatin 3 icotinib 2 Radiation 2 Paclitaxel 2 Gemcitabine 2 Gefitinib 2 Fluorouracil 2 Drug Therapy 2 Chemoradiotherapy 2 Carboplatin 2 sintilimab 1 rucaparib 1 regorafenib 1 olaparib 1 lenvatinib 1 iron isomaltoside 1000 1 ipatasertib 1 iopromide 1 gluconic acid 1 elemene 1 capecitabine-irinotecan combination 1 aumolertinib 1 atezolizumab 1 anlotinib 1 aflutinib 1 XELOX 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Adenocarcinoma × aflutinib × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡